A Phase 4 interventional study of Placebo matched to prednisone and Prednisone in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 39 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-01.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 4 that started in 2016, is one of 32 in phase 4, and was the 89th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 41st largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 28 in phase 4, and was the 198th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28] erythrocyte sedimentation rate [ESR]) from randomization to Week 24 post-randomization, in participants with stable low disease activity [LDA] (DAS28 ESR score less than or equal to [\<=] 3.2) who receive tocilizumab, and have been randomized to either continue or taper prednisone in a double-blinded fashion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Tocilizumab-experienced participants:
Tocilizumab-naïve participants:
Exclusion Criteria:
General
Disease-related
Previous or Concomitant Prohibited Therapy
Laboratory Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
Drug: Placebo matched to prednisone · Drug: Prednisone · Biological: Tocilizumab
Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
Drug: Placebo matched to prednisone · Drug: Prednisone · Biological: Tocilizumab
Participants will receive placebo matched to prednisone orally for 24 weeks.
Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint count, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100-millimeter (mm) visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Baseline to Week 24
Treatment Success
Treatment success was defined as the percentage of participants with stable low disease activity (LDA) (DAS28-ESR score ≤ 3.2) at Week 24 post-randomization, who did not suffer a flare due to RA and who showed no confirmed adrenal insufficiency that required replacement therapy. DAS28 has the following standardized cut-offs for disease activity and remission: DAS28 \> 5.1 = high disease activity; DAS28 between 3.2 and 5.1 = moderate disease activity; DAS28 ≤ 3.2 = low disease activity; DAS28 ≤ 2.6 = remission.
Time frame: Week 24
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index is calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter (cm) visual analog scale (VAS) + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 100 mm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores range from 0 to 76, with higher scores indicating increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Baseline and Week 24
Percentage of Participants With >=1 Flare
Percentage of participants with \>=1 flare
Time frame: 24 weeks
Time to First RA Flare
The mean time of onset for the first RA flare since randomization.
Time frame: Randomization to 24 weeks
Percentage of Visits With RA Flares
Time frame: Randomization to 24 weeks
Percentage of Participants With >=1 Administration of Flare Rescue Medication
The proportion of participants with at least one administration of RA flare rescue medication.
Time frame: Randomization to 24 weeks
Time to First Administration of Flare Rescue Medication
Time of onset of first administration of RA flare rescue medication since randomization date
Time frame: Randomization to 24 weeks
Number of Administrations of Flare Rescue Medication
Proportion of participants who received courses of RA flare rescue medication by number of courses received.
Time frame: Randomization to 24 weeks
Cumulative Prednisone Exposure (Dose)
In Post-randomization prednisone arm, Cumulative dose = (number of capsules taken during week 1 to 4 \* 1 mg) + (3/4 \* number of capsules taken during week 5 to 8 \* 1 mg) + (1/2 \* number of capsules taken during week 9 to 12 \* 1 mg) + (1/4 \* number of capsules taken during week 13 to 16 \* 1 mg). In continued arm, cumulative dose = (1/4 \* number of capsule taken \* 5 mg). Cumulative prednisone dose is defined as cumulative blinded prednisone + cumulative flare rescue prednisone.
Time frame: Randomization to 24 weeks
Percentage of Participants Who Maintain LDA (DAS28 ESR Score <=3.2) or Remission (DAS28 ESR Score <2.6) and the Percentage of Participants Who Maintain the Baseline Disease Activity Level
The proportion of participants who maintained LDA and the proportion of participants who maintained the baseline disease activity level at Week 24. LDA was defined as DAS28 ESR score \<= 3.2. Remission was defined as DAS28 ESR score \<= 2.6. Participants who maintained the baseline activity was defined as DAS28-ESR at Week 24 \<= DAS28-ESR at baseline.
Time frame: Randomization to Week 24
Percentage of Participants Who Permanently Discontinue Study Treatment Due to Insufficient Flare Control
Percentage of participants who permanently discontinue study treatment due to insufficient flare control
Time frame: 24 weeks
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Swollen 66 Joint Counts
Count of swollen joints based upon 66 assessed joints.
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Tender 68 Joint Counts
Count of tender joints based on 68 assessed joints.
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Assessment of Pain
The ACR patient's assessment of pain is scored on a visual analog scale (VAS) from 0 (no pain) to 100 mm (unbearable pain). A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Global Assessment of Disease Activity
The ACR patient's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Physician's Global Assessment of Disease Activity
The ACR physician's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Health Assessment Questionnaire-Disability Index (HAQ-DI)
A measure of self-perceived disability containing 20 questions in eight categories and including additional section about aid from other people and devices needed to correct the disabilities. Scores range from 0 to 3, with higher scores indicating worse disability.
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: High Sensitivity C-Reactive Protein (hsCRP)
Change from baseline in the acute phase reactant hsCRP
Time frame: Baseline to Week 24
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Erythrocyte Sedimentation Rate (ESR)
Change from baseline in the acute phase reactant ESR
Time frame: Baseline to Week 24
Changes From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Final Score
The RAID is a participant-completed questionnaire specific for RA consisting of a 0-10 rating for pain, functional disability, fatigue, sleep, physical well-being, emotional well-being and coping. Scores are weighted to produce a final numerical result. A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Baseline and Week 24
Changes From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Score
The WPAI:SHP is a 6-item questionnaire to measure performance impairment of work and regular daily activity and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score range from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicate greater impairment and less productivity. A positive change in score indicates impairment, and a negative change indicates improvement.
Time frame: Baseline and Week 24
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 24
The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count based on a 28-joint assessment, patient and physician global assessment of disease activity according to 100-mm visual analog scale (VAS) and level of C-reactive protein in milligrams per deciliter (mg/dL, normal \<1 mg/dl). The total SDAI score range is 0-86, where higher scores indicate increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.
Time frame: Randomization to Week 24
| Milestone | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Started | 131 | 128 |
| Completed | 116 | 113 |
| Not completed | 15 | 15 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Lack of efficacy | 5 | 4 |
| Withdrew: Non-compliance | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Study ended per protocol | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 |
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint count, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100-millimeter (mm) visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.
| Score on a scale | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization | 0.538 (0.346 to 0.729) | -0.075 (-0.271 to 0.121) |
Treatment success was defined as the percentage of participants with stable low disease activity (LDA) (DAS28-ESR score ≤ 3.2) at Week 24 post-randomization, who did not suffer a flare due to RA and who showed no confirmed adrenal insufficiency that required replacement therapy. DAS28 has the following standardized cut-offs for disease activity and remission: DAS28 \> 5.1 = high disease activity; DAS28 between 3.2 and 5.1 = moderate disease activity; DAS28 ≤ 3.2 = low disease activity; DAS28 ≤ 2.6 = remission.
| Percentage of Participants | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Treatment Success | 64.9 (56.1 to 73.0) | 77.3 (69.1 to 84.3) |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index is calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter (cm) visual analog scale (VAS) + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 100 mm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores range from 0 to 76, with higher scores indicating increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.
| Score on a scale | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24 | 2.663 (1.454 to 3.872) | 0.321 (-0.914 to 1.556) |
Percentage of participants with \>=1 flare
| Percentage of Participants | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Percentage of Participants With >=1 Flare | 26.0 | 10.9 |
The mean time of onset for the first RA flare since randomization.
| Weeks | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Time to First RA Flare | 15.64 ± 7.13 | 12.11 ± 7.96 |
| Percentage of visits with flares | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| 1 Visit | 16.0 | 7.0 |
| 2 Visits | 6.9 | 3.9 |
| 3 Visits | 2.3 | 0 |
| >3 Visits | 0.8 | 0 |
The proportion of participants with at least one administration of RA flare rescue medication.
| Percentage of Participants | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Percentage of Participants With >=1 Administration of Flare Rescue Medication | 20.6 | 6.3 |
Time of onset of first administration of RA flare rescue medication since randomization date
| Weeks | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Time to First Administration of Flare Rescue Medication | 13.59 ± 6.77 | 8.76 ± 5.26 |
Proportion of participants who received courses of RA flare rescue medication by number of courses received.
| Percentage of Participants | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| 0 courses | 79.4 | 93.8 |
| 1 course | 15.3 | 3.9 |
| 2 courses | 4.6 | 1.6 |
| 3 courses | 0 | 0.8 |
| >3 courses | 0.8 | 0 |
In Post-randomization prednisone arm, Cumulative dose = (number of capsules taken during week 1 to 4 \* 1 mg) + (3/4 \* number of capsules taken during week 5 to 8 \* 1 mg) + (1/2 \* number of capsules taken during week 9 to 12 \* 1 mg) + (1/4 \* number of capsules taken during week 13 to 16 \* 1 mg). In continued arm, cumulative dose = (1/4 \* number of capsule taken \* 5 mg). Cumulative prednisone dose is defined as cumulative blinded prednisone + cumulative flare rescue prednisone.
| mg | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Cumulative blinded prednisone dose | 267.099 ± 40.048 | 769.459 ± 175.882 |
| Cumulative flare rescue prednisone dose | 98.519 ± 51.921 | 121.875 ± 54.898 |
| Cumulative prednisone dose | 287.405 ± 63.184 | 777.136 ± 172.881 |
The proportion of participants who maintained LDA and the proportion of participants who maintained the baseline disease activity level at Week 24. LDA was defined as DAS28 ESR score \<= 3.2. Remission was defined as DAS28 ESR score \<= 2.6. Participants who maintained the baseline activity was defined as DAS28-ESR at Week 24 \<= DAS28-ESR at baseline.
| Percentage of Participants | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| LDA at baseline | 97.7 | 96.9 |
| LDA at Week 24 | 73.4 | 83.1 |
| Baseline DAS28-ESR ≤ 2.6 | 78.6 | 76.6 |
| Remission at Week 24 | 61.2 | 81.6 |
| Maintained baseline activity at Week 24 | 36.6 | 54.7 |
Percentage of participants who permanently discontinue study treatment due to insufficient flare control
| Percentage of Participants | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Percentage of Participants Who Permanently Discontinue Study Treatment Due to Insufficient Flare Control | 0 | 0.8 |
Count of swollen joints based upon 66 assessed joints.
| Swollen joints | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Swollen 66 Joint Counts | 0.129 ± 6.687 | -0.107 ± 1.618 |
Count of tender joints based on 68 assessed joints.
| Tender joints | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Tender 68 Joint Counts | 0.793 ± 7.764 | -0.330 ± 2.729 |
The ACR patient's assessment of pain is scored on a visual analog scale (VAS) from 0 (no pain) to 100 mm (unbearable pain). A positive change in score indicates worsening, and a negative change indicates improvement.
| mm | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Assessment of Pain | 4.648 ± 24.315 | -8.010 ± 25.980 |
The ACR patient's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.
| cm | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Global Assessment of Disease Activity | 0.280 ± 2.000 | -0.153 ± 1.506 |
The ACR physician's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.
| cm | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Physician's Global Assessment of Disease Activity | 0.345 ± 1.463 | -0.248 ± 1.167 |
A measure of self-perceived disability containing 20 questions in eight categories and including additional section about aid from other people and devices needed to correct the disabilities. Scores range from 0 to 3, with higher scores indicating worse disability.
| Score on a scale | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Health Assessment Questionnaire-Disability Index (HAQ-DI) | 0.167 ± 0.486 | -0.087 ± 0.527 |
Change from baseline in the acute phase reactant hsCRP
| mg/dL | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: High Sensitivity C-Reactive Protein (hsCRP) | -0.135 ± 1.470 | -0.040 ± 0.277 |
Change from baseline in the acute phase reactant ESR
| mm/hr | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Erythrocyte Sedimentation Rate (ESR) | 1.517 ± 7.892 | -0.679 ± 5.433 |
The RAID is a participant-completed questionnaire specific for RA consisting of a 0-10 rating for pain, functional disability, fatigue, sleep, physical well-being, emotional well-being and coping. Scores are weighted to produce a final numerical result. A positive change in score indicates worsening, and a negative change indicates improvement.
| Score on a scale | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Changes From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Final Score | 0.469 ± 2.109 | -0.220 ± 1.940 |
The WPAI:SHP is a 6-item questionnaire to measure performance impairment of work and regular daily activity and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score range from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicate greater impairment and less productivity. A positive change in score indicates impairment, and a negative change indicates improvement.
| Score on a scale | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Percent work time missed due to problem | 4.535 ± 23.283 | 0.572 ± 31.455 |
| Percent impairment while working due to problem | -0.851 ± 24.920 | -5.584 ± 23.343 |
| Percent overall work impairment due to problem | 6.219 ± 29.223 | -6.191 ± 30.531 |
| Percent activity impairment due to problem | 3.398 ± 23.786 | -4.190 ± 21.608 |
The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count based on a 28-joint assessment, patient and physician global assessment of disease activity according to 100-mm visual analog scale (VAS) and level of C-reactive protein in milligrams per deciliter (mg/dL, normal \<1 mg/dl). The total SDAI score range is 0-86, where higher scores indicate increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.
| Score on a scale | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 24 | 2.511 (1.296 to 3.727) | 0.248 (-0.994 to 1.489) |
Collected over Randomization to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab+Prednisone (Tapering Dose) | 0/131 (0%) | 7/131 (5.3%) | 46/131 (35.1%) |
| Tocilizumab+Prednisone (Constant Dose) | 0/128 (0%) | 4/128 (3.1%) | 21/128 (16.4%) |
| Event | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| PNEUMONIAInfections and infestations | 1/131 | 1/128 |
| CELLULITIS GANGRENOUSInfections and infestations | 0/131 | 1/128 |
| SCIATICANervous system disorders | 0/131 | 1/128 |
| DRUG HYPERSENSITIVITYImmune system disorders | 0/131 | 1/128 |
| PSYCHOTIC DISORDERPsychiatric disorders | 0/131 | 1/128 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 0/131 | 1/128 |
| SPINAL COLUMN STENOSISMusculoskeletal and connective tissue disorders | 1/131 | 0/128 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/131 | 0/128 |
| NEUTROPENIABlood and lymphatic system disorders | 1/131 | 0/128 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/131 | 0/128 |
| Event | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 13/131 | 9/128 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 9/131 | 3/128 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 9/131 | 2/128 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 8/131 | 2/128 |
| DIARRHOEAGastrointestinal disorders | 7/131 | 5/128 |
| Age, Continuous(Years) | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) | Total |
|---|---|---|---|
| Mean | 54.8 ± 14.0 | 54.0 ± 12.8 | 54.4 ± 13.4 |
| Sex: Female, Male(Participants) | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) | Total |
|---|---|---|---|
| Female | 103 | 97 | 200 |
| Male | 28 | 31 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 120 | 114 | 234 |
| Unknown or Not Reported | 10 | 14 | 24 |
| Race (NIH/OMB)(Participants) | Tocilizumab+Prednisone (Tapering Dose) | Tocilizumab+Prednisone (Constant Dose) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| Black or African American | 0 | 0 | 0 |
| White | 129 | 123 | 252 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Feb 2018, 22 months.
Results were first posted in Jul 2019, 1 year 5 months after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 22 months is below that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab